November 20, 2026

Bangladesh reduces prices for 10 types of heart stents from three international companies

The move will lower the cost from two producers by Tk 3,000 to Tk 88,000

 Senior Correspondent

bdnews24.com

Published : 05 Aug 2025, 12:26 AM

Updated : 21 Aug 2026, 01:36 PM

The government has decided to reduce the prices of 10 types of coronary stents produced by three international companies for cardiac treatment in Bangladesh.

The move will lower the cost from two producers by amounts ranging from Tk 3,000 to a maximum of Tk 88,000.

When blood flow through the artery is blocked, a stent or coronary stent is placed through angioplasty to help maintain the normal functions of the heart.

Commonly, this is known as a "ring”.

The Ministry of Health and Family Welfare issued a gazette notification on the matter on Sunday, following the recommendation of a specialist advisory committee formed to review the pricing of coronary stents.

The notification, signed by Muhammad Mustafizur Rahman, senior assistant secretary of the Health Services Division, said that based on the recommendations of the advisory committee, the maximum retail prices of coronary stents imported from Boston Scientific, Abbott, and Medtronic have been approved, taking into account taxes, VAT, charges or commissions, and reasonable profit margins for the companies.

According to the notice, the price of Resolute Onyx, produced by Medtronic, has been reduced from Tk 140,500 to Tk 90,000.

The cost of Onyx Trucor from the same company has been lowered from Tk 72,000 to Tk 50,000.

In addition, Boston Scientific's Promus ELITE price has been cut from Tk 79,000 to Tk 72,000, Promus PREMIER from Tk 73,000 to Tk 70,000, Synergy from Tk 117,000 to Tk 90,000, Synergy SHIELD from Tk 120,000 to Tk 90,000, and Synergy XD from Tk 188,000 to Tk 100,000.

For Abbott, the price of Xience Prime stent ring has been dropped from Tk 66,600 to Tk 50,000, Xience Alpine from Tk 140,500 to Tk 90,000, and Xience Sierra from Tk 140,000 to Tk 90,000.

The gazette states that hospitals must not charge more than 5 percent as a service fee on top of the fixed stent prices.

The Directorate General of Health Services (DGHS) and the Directorate General of Drug Administration (DGDA) have been instructed to ensure this is enforced.

The notification also reads that appropriate measures must be taken to prevent the purchase of any cardiovascular or neuro-implant devices at prices exceeding the approved maximum retail prices.

Earlier, in the first week of April last year, the DGDA had set prices for 23 types of stents from multiple companies.

Related Stories